Inicio>>Signaling Pathways>> Angiogenesis>> Integrin>>Zaurategrast ethyl ester

Zaurategrast ethyl ester

Catalog No.GC37961

El éster etÍlico de zaurategrast (CDP323), el profÁrmaco de éster etÍlico de CT7758, es un antagonista de la integrina α4β1/α4β7 que se utiliza para el tratamiento de trastornos inflamatorios y autoinmunes.

Products are for research use only. Not for human use. We do not sell to patients.

Zaurategrast ethyl ester Chemical Structure

Cas No.: 455264-30-9

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
436,00 $
Disponible
5mg
360,00 $
Disponible
10mg
621,00 $
Disponible
25mg
1.125,00 $
Disponible
50mg
1.800,00 $
Disponible
100mg
2.880,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Zaurategrast ethyl ester (CDP323), the ethyl ester prodrug of CT7758[1], is a α4β1/α4β7 integrin antagonist used for the treatment of inflammatory and autoimmune disorders[2]. α4β1/α4β7 integrin[1]

Zaurategrast ethyl ester (CDP323), an ethyl ester prodrug of CT7758, shows some improvements in increasing mass transfer[1].

[1]. Chanteux H, et al. Cross-Species Differences in the Preclinical Pharmacokinetics of CT7758, an α4β1/α4β7 Integrin Antagonist. Drug Metab Dispos. 2015 Sep;43(9):1381-91. [2]. Davenport RJ, et al. Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases• Drug Discov Today. 2007 Jul;12(13-14):569-76.

Reseñas

Review for Zaurategrast ethyl ester

Average Rating: 5 ★★★★★ (Based on Reviews and 18 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Zaurategrast ethyl ester

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.